President and CEO of Neurocrine Biosciences Inc. (NBIX, Financial) Kevin Charles Gorman sells 9,445 shares of NBIX on 01/12/2010 at an average price of $2.52 a share.
Neurocrine Biosciences Inc. has a market cap of $100 million; its shares were traded at around $2.55 with and P/S ratio of 25.2. Neurocrine Biosciences Inc. had an annual average earning growth of 21.7% over the past 5 years.
Neurocrine Biosciences Inc. has a market cap of $100 million; its shares were traded at around $2.55 with and P/S ratio of 25.2. Neurocrine Biosciences Inc. had an annual average earning growth of 21.7% over the past 5 years.
Directors and Officers Recent Trades:
- Buy:: Director W Thomas Mitchell bought 900 shares of NBIX stock on 11/05/2009 at the average price of 2.17, the price of the stock has increased by 17.51% since.
- Sell:: Sr. VP & Chief Medical Officer Christopher Flint Obrien sold 1,503 shares of NBIX stock on 01/04/2010 at the average price of 2.65, the price of the stock has decreased by 3.77% since.
- Sell:: Sr Vice President, Development Haig P. Bozigian sold 751 shares of NBIX stock on 01/04/2010 at the average price of 2.64, the price of the stock has decreased by 3.41% since.
- Sell:: Vice President, Research Dimitri E. Grigoriadis sold 1,503 shares of NBIX stock on 01/04/2010 at the average price of 2.67, the price of the stock has decreased by 4.49% since.
- Sell:: Sr Vice President, Development Haig P. Bozigian sold 3,642 shares of NBIX stock on 09/28/2009 at the average price of 3.11, the price of the stock has decreased by 18.01% since.
